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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of consumer guidelines for people with chronic illnesses, on health outcomes.
B A C K G R O U N D
Description of the condition
Chronic illnesses are characterised by their long duration and gen-
erally slowprogression (WHO 2012). They are not limited tonon-
communicable diseases; further, public health specialists increas-
ingly view some diseases that were formerly considered to be ter-
minal (such as HIV/AIDS and some cancers) as chronic illnesses.
These conditions require long-term, ongoing and comprehensive
health services similar to other recognised chronic illnesses such
as diabetes or cardiovascular disease (Kitihata 2002). Chronic ill-
nesses as defined for this review include both physical and mental
illnesses (WHO 2012). The World Health Organisation (WHO)
has projected that the proportion of deaths due to chronic illnesses
would rise from 59% in 2002 to 69% in 2030 (WHO 2002).
More recently, WHO reported that chronic diseases such as heart
disease, stroke, cancer, chronic respiratory diseases and diabetes
are the leading causes of mortality in the world, representing 60%
of all deaths (WHO 2012).
A significant proportion of people with chronic illness do not
receive appropriate care (Schoen 2009). Studies in the United
States and Netherlands suggest that 30 to 40% of patients do not
receive care according to current scientific evidence, while 20%
or more of the care provided is not needed, or may be harmful to
patients (Grol 2003; Garman 2006). McGlynn 2003, surveying
12 metropolitan areas in the United States, found that only 56%
of people with chronic illnesses received recommended medical
treatment. An examination of the experiences of chronically-ill
patients across eight countries found major differences in access,
safety and care efficiency, with these patients at particular risk of
experiencing inefficient, poorly-organised care or errors (Schoen
2009).
There are a number of reasons as to why people with chronic ill-
ness do not receive the type and level of care that is recommended.
Deficits in care management during hospital discharge or when
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seeing multiple doctors are common (Schoen 2009), highlighting
the need for system innovations to improve outcomes for patients
with complex chronic illnesses. A survey of ’sicker adults’ across
Australia, Canada, New Zealand, UK and USA, reported that 33
to 49% of respondents were not given advice on health risk be-
haviours (such as weight, nutrition, exercise, smoking and at risk
alcohol use) and that 47 to 67% were not asked for their input
into treatment options (Blendon 2003). Another concern relates
to inadequate patient involvement in health care, which is partic-
ularly evident in mental health. Reports have found that less than
15% of patients with chronic illnesses such as major depression,
panic disorder or generalised anxiety disorder, receive evidence-
based treatment (Wang 2000;Horsfall 2010). People with chronic
illnesses may not have adequate control of their condition (Frijling
2001; Primatesta 2004; McKinstry 2006) and general practition-
ers can overestimate patients’ adherence to guidelines (Steinman
2004).
People with chronic illnesses increasingly are expected to con-
tribute to decision making around their health care and disease
management (Montori 2006), but they do not always have access
to appropriate evidence-based information. As a result, some pa-
tients will turn to resources such as the Internet which may not
always offer themost appropriate information, as theymay be out-
of-date, or may reflect the views of specific interest groups (e.g.,
pharmaceutical companies or professional associations). In some
cases the advice thus obtained can have negative health conse-
quences (Eysenbach 1999; Hardey 2001; Scullard 2010). Recent
research into the accuracy and reliability of medical advice over
the internet found that news sites only gave correct advice in 55%
of cases (based on current United Kingdom gold standard recom-
mendations), whilst no sponsored sites encountered in the study
gave the correct advice (Scullard 2010). There is, therefore, a need
for accurate and reliable information for people with chronic dis-
eases.
Increasingly, clinicians have become aware of the impact of using
patients’ expertise to assist with their own disease management
(DOH2001; Epping-Jordan 2001;Wagner 2001; Kennedy 2002;
Martinez 2009; Musacchio 2011). However, clinical and research
developments in this area have been slow. This may be partly due
to the anxieties and skepticism of some healthcare professionals,
who fear that more, rather than less time will be needed to man-
age ’expert’ patients (Shaw 2004; Fox 2005). Additional barriers
relate to conflicting notions of who is responsible for managing
the illness: the patient or their care provider (Anderson 2005; Fox
2005; Gagliardi 2008). It has been reported that not all patients
want to be accountable for the overall management of their health
(Henwood 2003), believing instead that this is the role of their
healthcare professional. In addition, a 2005 study found that pa-
tients felt that they did not possess the technical competence to
become adept in self-management (Fox 2005).
Description of the intervention
For the purpose of this review a consumer self-care guideline is an
educational guideline designed to encourage patient participation
in themanagement of their chronic disease.Wewill include guide-
lines provided to patients by a healthcare professional that seek
to enhance their understanding of their illness and recommend
standards of care and treatment options to be discussed with their
healthcare professional. Guidelines are increasingly produced by
a wide range of organisations, but we will include only those pro-
duced in consultation with health professionals or are accepted as
an established national guideline.
Consumer self-care guidelines as defined for this review are aimed
at two areas, firstly to promote self-care or self-management by in-
creasing patient participation in the management of their chronic
disease, and secondly to enhance patient understanding of their
illness. Promotion of self-care seeks to encourage people to take re-
sponsibility for their own health and well-being. According to the
National Health Service (NHS 2009), self-care is a working part-
nership between the individual and their care professional by com-
munication, negotiation and decision-making processes to achieve
the best possible outcome for the individual. Self-care refers to
empowering individuals in a supportive, non-threatening manner,
by promoting health and well-being and providing tools and re-
sources to manage their own healthcare needs.
Extensive, well-researched guidelines exist for all chronic illnesses,
including chronic obstructive pulmonary disease (GOLD 2010),
asthma, (Kroegel 2009), hypertension (AACE 2006), type II di-
abetes (RACGP 2011), irritable bowel syndrome (NICE 2008)
and depression (CBC 2011). Clinical guidelines can use differ-
ent types of evidence with varying levels of validity and reliability
(Higgins 2011;Hillier 2011). Consolidating an often complicated
body of evidence can be problematic for guideline developers, and
where empirical evidence is not available, guidelines may use con-
sensus-based expert opinion or provide recommendations with a
disclaimer that the area requires further research (Gagliardi 2009).
Numerous tools have beendeveloped todetermine the reliability of
such evidence, including the Jadad score (Clark 1999), NHMRC
evidence ratings (NHMRC 2009), FORM (Hillier 2011) and
GRADE tools (Grading of Recommendations Assessment, Devel-
opment, and Evaluation) (Guyatt 2011). These assessments are
important when considering the reliability of such information
for consumer self-care guidelines and this will be examined within
the review.
How the intervention might work
Consumer self-care guidelines might work by providing patients
with the resources so that they can take a more active role in their
health care. Patients with effective self-management skills report-
edlymake better use of health professionals’ time and subsequently
have enhanced self-care (Barlow 2000; Bourbeau 2009). Evidence
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suggests that some patients want a more active role in their health
care (Anderson 1995; Anderson 1996; Day 2000; Montori 2006)
and this results in increased feelings of control, which one au-
thor suggestsmay have significant health benefits (Kennedy 2006).
Through everyday decisions, which are influenced by attitudes
and knowledge regarding medications, self-management and ex-
ercise, people with chronic illnesses will influence the course and
severity of their disease (Bourbeau 2009) as well as their every-
day quality of life. In the primary care setting there is increasing
evidence that patients’ expectations of treatment have significant
effects on the treatment they actually receive from their healthcare
provider (Howitt 1999; Tomlin 1999; McKinstry 2006). Giving
consumers guidelines containing the latest evidence-based recom-
mendations for treating their chronic condition may prompt them
to talk with their physician about treatment options. Reducing the
need for professional input may increase the cost-effectiveness of
care and reduce ’inappropriate’ demands on healthcare providers
(Troop 1993; Kennedy 2006). Moreover, guidelines synthesise a
large amount of information. Given the magnitude of new evi-
dence, and the gap that already exists, patient-directed educational
resources offer a potential bridge to narrow this gap (Smith 2003).
Why it is important to do this review
In conducting this review we aim to consolidate and critically
analyse trials of consumer-directed self-care guidelines for chronic
diseases, in order to uncover which strategies work best for ap-
propriate, acceptable and effective patient care. As a result this re-
view will act as a guide for future clinical practice initiatives and
health service investment in patient-directed resources. Incorpo-
rating new knowledge into clinical practice has been slow, un-
even and at times resisted (Garman 2006). Providing evidence-
based resources to patients is considered vital to enable them to
more actively manage their health (WHO 2005). As treatment
of chronic illness is being directed increasingly at the community
level, the role of the patient in understanding and managing their
own health is growing more important (Coster 2009). There is lit-
tle evidence consolidation on this intervention, which may prove
to be a cost-effective approach to patient self-care.
O B J E C T I V E S
To assess the effects of consumer guidelines for people with chronic
illnesses, on health outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials, including cluster randomised con-
trolled trials.
Types of participants
People with a chronic disease meeting the World Health Organ-
isation definition, being ’a disease of long duration and generally
slow progression’ (WHO 2012), in contrast to an acute illness
which is expected to resolve completely within a relatively short
period of time.
Chronic diseases include asthma, chronic obstructive pulmonary
disease, hypertension, irritable bowel syndrome, diabetes mellitus,
Ischaemic heart disease, epilepsy, schizophrenia, depression, anx-
iety, Parkinson’s disease, Alzheimer’s disease, HIV/AIDS, cancer,
arthritis and renal failure (WHO 2012). Obesity (as defined by
study authors) will also be considered as a chronic disease (Bray
2004).
We will exclude studies of people without an established chronic
illness, such as those who only have a family history of a disease
or who have high risk factors.
We will include people of all age groups, as well as informal care-
givers and parents of children with a chronic illness, who also re-
ceive the intervention.
Types of interventions
The primary purpose of a consumer guideline is to provide
a patient with an easy-to-follow resource, which will enable a
more practical approach to self-management in collaboration with
healthcare providers, and enhance their understanding of the ill-
ness. To be included in this review, guidelines assessed in studies
must:
• include a recommendation for standards of care that should
be met with treatment options (i.e., provide suggested treatments
within the guideline for the health problems reported);
• be delivered or initiated by a healthcare professional or
healthcare worker, such as a doctor, surgeon, visiting ward
specialist, nurse, therapist, pharmacist, dietician or researcher, to
the patient; and
• be produced in consultation with a healthcare professional,
recognised healthcare organisation, or established recognised
guideline with the aim of increasing patient participation in
chronic disease management.
The intervention could be delivered in various ways, such as face-
to-face, via the internet, email or post.
Comparison: No intervention, usual practice, oral education only,
minimal written information e.g., pamphlet or standard informa-
tion or a guideline of comparable intensity, that is not used for
chronic disease management.
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Types of outcome measures
Primary outcomes
1. Consumer reported physical health outcomes (including symp-
tom scores or counts related to the disease such as breathlessness,
pain scales, tiredness, frequency of bowel movements etc.)
2. Psychological health outcomes (including validated quality of
life measures, anxiety and depression scales)
3. Adverse outcomes such as mortality and adverse health events
Secondary outcomes
4. Consumer behaviour (use of guideline recommendations, such
as change in use of vaccinations, scans, blood tests, or medication,
or involvement in the decision-making process)
5. Consumer knowledge or mastery (level of knowledge or change
in knowledge about the disease, illness, treatment) and attitudes
(towards the illness, treatment)
6. Process measures (patient-reported guideline usage, reading of
the guideline, talked/showed doctor the guideline)
7. Clinical treatment outcomes (including results of investigations
such as pulmonary function testing, BMI, biopsies and haemato-
logical and biochemical tests)
8. Acceptability of guidelines to the consumer (including satisfac-
tion with the information provided, satisfaction with how it was
offered, effectiveness of support provided)
9. Service-delivery outcomes including medical service utilisation
and costs to the health system
Search methods for identification of studies
Electronic searches
We will search the following electronic databases:
• The Cochrane Central Register of Controlled Trials
(CENTRAL, The Cochrane Library, latest issue);
• MEDLINE (OvidSP) (1966 to present);
• EMBASE (OvidSP) (1980 to present);
• PsycINFO (OvidSP) (1966 to present);
• ERIC (1966 to present).
We present the search strategy for MEDLINE (OvidSP) in
Appendix 1. The search strategies for other databases will be
adapted as appropriate. There will be no language or date restric-
tions.
Searching other resources
We will review reference lists of all included studies and of re-
lated reviews to identify potentially relevant citations. In addition,
we will make enquiries regarding other published or unpublished
studies known to the authors of included studies.
We will search online clinical trial registers for ongoing and
recently completed studies, including Controlled Clinical Tri-
als (www.controlled-trials.com), the National Research Regis-
ter (www.nrr.nhs.uk), government registries (clinicaltrials.gov),
WHO registries (http://apps.who.int/trialsearch/) and Trials Cen-
tral (www.trialscentral.org).
Data collection and analysis
Selection of studies
We will combine search results using reference management soft-
ware and remove duplicates.
From the title, abstract, or descriptors, KC and NL will indepen-
dently review all citations identified through the searches to de-
termine potentially-relevant trials. All potentially-relevant studies
that clearly do not meet the inclusion criteria will be excluded
and the reasons recorded in a table ’Characteristics of Excluded
Studies’. Any disagreements will be resolved either by consensus or
discussion with a third party (BS).We will collate multiple reports
of the same study.
Data extraction and management
A combination of two independent review authors (KC and either
NL or MB) will extract the study characteristics, risk of bias data
(see Assessment of risk of bias in included studies) and outcome
data for all included studies. We will extract data using a standard-
ised form based on the Cochrane Consumer and Communication
Review Group’s data extraction template (CCRG 2009), before
entering it into The Cochrane Collaboration software program
Review Manager. KC will correspond with study authors to re-
quest any missing or raw data as required. Any disagreements will
be resolved either by consensus or inclusion of a third party BS.
We will extract the following information from included studies:
• Methods: aim of study; study design; participant
recruitment methods; inclusion/exclusion criteria; informed
consent; ethical approval; funding; statistical methods; and
consumer involvement;
• Participants: description; geographical location; setting; n-
values; age; gender; ethnicity; language; diagnosis; co-
morbidities; stage/duration of illness; current treatment; and
socio-economic status;
• Interventions: aim of intervention; descriptions of
interventions and controls; theoretical basis/source; duration;
intervention delivery; provider details; and fidelity/integrity of
guidelines (based on reported use of validated guideline
resources, attempts to test validity of completed consumer
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guideline and involvement of field experts in creation of the
consumer guideline);
• Outcomes: outcome data as specified under ’Types of
outcome measures; method of outcome collection; method of
follow-up for non-respondents; timing of outcome assessments;
and adverse events.
• Risk of bias: see Assessment of risk of bias in included
studies.
Assessment of risk of bias in included studies
We will assess and report on the methodological risk of bias of
included studies in accordance with the Cochrane Handbook
(Higgins 2011) and the guidelines of the Cochrane Consumers
and Communication Review Group (Ryan 2011), which recom-
mends the explicit reporting of the following individual elements
for RCTs: random sequence generation; allocation sequence con-
cealment; blinding (participants, personnel); blinding (outcome
assessment); completeness of outcome data, selective outcome re-
porting; other sources of bias.
In all cases, two authors will independently assess the risk of bias
of included studies, with any disagreements resolved by discus-
sion and consensus. We will contact study authors for additional
information about the included studies, or for clarification of the
study methods as required. We will incorporate the results of the
risk of bias assessment into the review through standard tables,
and systematic narrative description and commentary about each
of the elements, leading to an overall assessment the risk of bias
of included studies and a judgement about the internal validity of
the review’s results. Risk of Bias for each domain will be assessed
as ’high risk of bias’, ’low risk of bias’ or ’unclear risk of bias’ as
per the guidelines from table 8.5.d of the Cochrane Handbook
(Higgins 2011).
Measures of treatment effect
If possible, a risk ratio (RR) or odds ratio (OR) will be provided
for the primary outcome of each trial for dichotomous data and
standardised mean difference (SMD) or mean difference (MD)
for continuous data. These effect estimates will be standardised
so that ratios greater than one and differences between interven-
tion and control groups greater than zero, indicate benefit for the
intervention group. Where appropriate, the differences in change
scores for relevant outcomes will be analysed. Where required, the
statistician AE will be consulted for further advice. In instances
where more than one outcome is being reported for each outcome
category, we will select the reported outcome that is most closely
related to the main purpose of the guideline.
Where repeated measures over time are reported for a single study
outcome, the longest follow-up will be used for meta-analyses,
whilst each time period will be extrapolated using narrative syn-
theses and reported in the tables described under Data synthesis
below.
Unit of analysis issues
For cluster controlled trials, we will perform the analysis at the
level of individual whilst accounting for clustering in the data. For
those studies which did not adjust for clustering the actual sample
size will be replacedwith the effective sample size (ESS), calculated
using a rho = 0.02 as per Campbell 2000 and the Cochrane Hand-
book, section 16.3.4 (Higgins 2011). Trials may use a variety of
statistical methods to investigate or compensate for clustering; we
will record whether studies used these andwhether the significance
of any effect was altered.
In the case of multi-arm trials we will include each pair-wise com-
parison separately, but with shared intervention groups divided
out approximately evenly among the comparators. However, if
the intervention groups are deemed similar enough to be pooled,
the groups will be combined using appropriate formulas in the
Cochrane Handbook (table 7.7.a for continuous data and chapter
16.5.4 for dichotomous data) (Higgins 2011).
Dealing with missing data
We will deal with missing data using an available case analysis
basis as described in chapter 16.2.2 of the Cochrane Handbook
(Higgins 2011). All treatment effects will be based on an inten-
tion-to-treat analysis where possible. In the case of missing sum-
mary statistics required formeta-analysis (e.g., standard deviations,
means and n-values) we will attempt to contact study authors to
obtain this information. Loss of participants that occurred before
baseline measurements will be assumed to have no effect on the
outcome data of the study. We will assess and discuss any losses
after the baseline measurements are taken.
Assessment of heterogeneity
Significant heterogeneity is expected in this review due to the likely
diversities in the populations and diseases being examined.Within
meta-analyses, significant heterogeneity will be determined by a
combination of the I2 statistic (> 60%), the Chi2 statistic (P value
of less than 0.05) and visual inspection of the data. In such in-
stances data analysis using the random-effects model will be con-
sidered in place of a fixed-effect model. However this will be per-
formed with caution taking into account the possible influence
of smaller studies which could over- or under-estimate the true
treatment effect. If there are sufficient studies, we will also create
tables to examine heterogeneity by comparing effect sizes accord-
ing to potential effect modifiers (characteristics of the consumer
guidelines, single or co-morbid conditions, types of conditions
and quality of the comparisons).
Assessment of reporting biases
Providing that more than ten studies are included, we will assess
potential reporting biases using a funnel plot. Asymmetry in the
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plot could be attributed to publication bias, but may well be due
to true heterogeneity, poor methodological design or artefact. In
case of asymmetry, we may include contour lines corresponding to
perceived milestones of statistical significance (P = 0.01, 0.05, 0.1
etc.) to funnel plots, which may help to differentiate asymmetry
due to publication bias from that due to other factors (Higgins
2011). If fewer than ten studies are included, we will describe the
reporting biases in the ’other bias’ section of the risk of bias tables.
Data synthesis
We will conduct meta-analyses if relevant, valid data are available
from at least two studies of the same design, with interventions
that are conceptually similar and measure the same outcome. An
estimated pooled weight average for RRs will be calculated using
the Mantel-Haenszel fixed-effect model, with 95% confidence in-
tervals.Wewill use a fixed-effect model for meta-analyses, with the
exception of data presenting significant heterogeneity, where the
random-effects model will be used. If meta-analysis is not judged
appropriate we will use a narrative synthesis, treating the studies
individually with consideration of their confidence intervals or
reporting the results restricted to the larger, more rigorous stud-
ies as suggested in section 10.4.4.1 of the Cochrane Handbook
(Higgins 2011). In the presence of multiple variables presented
for one study (such as symptom scores), we will extract data on
the primary outcome (as defined by the authors of the study) for
meta-analysis if appropriate. However, if the study reports more
than one outcome and none of them are denoted as the primary
variable, we will rank the effect sizes for the variables and take the
median value. A summary table including a narrative synthesis
of all studies with effect sizes will be presented for the primary
and secondary outcomes. We will analyse these data using Review
Manager software.
Subgroup analysis and investigation of heterogeneity
Where meta-analysis is possible, heterogeneity may be explored
through the following subgroup analyses:
• Disease type being single or co-morbid disease and
classifications (e.g., COPD, asthma, irritable bowel syndrome,
hypertension etc.), as the impact of disease, treatment and
subsequent outcomes are known to vary between classifications.
• Length of follow-up (i.e., less than 12 months or greater
than or equal to 12 months), as some outcomes may be time
dependant producing different short- compared to long-term
results, such as quality of life.
• Intervention characteristics (i.e., printed or electronic
guideline, size of guideline and duration of intervention
delivery), as consumers may find printed material more user
friendly compared to electronic guidelines, however electronic
guidelines may be easier to access; a larger guideline may be more
intimidating reducing uptake, however a smaller guideline may
not be as comprehensive; brief intervention delivery may not be
as effective as a more intensive delivery of longer duration,
however the difference may not meet the minimally important
difference justifying the increased costs and consumer time
burden.
Sensitivity analysis
We will conduct sensitivity analyses by excluding studies with a
high risk of bias for sequence generation and/or allocation con-
cealment, and studies with participants who have significant co-
morbidities. Pecularities of studies under investigation may also be
discovered during the review process that require sensitivity analy-
sis as per section 9.7 of the Cochrane Handbook (Higgins 2011).
Consumer participation
Before conducting the review, the protocol was reviewed by two
independent consumers suffering from a chronic illness. Con-
sumers were presented with a list of questions relating to the de-
sign and layout of the protocol and asked to comment on these.
Upon completion of the review two independent consumers suf-
fering from a chronic illness will be asked to provide feedback and
comment on the findings of the review. The protocol and review
also received feedback from one or more consumers through the
Cochrane Consumers and Communication Review Group’s stan-
dard editorial process.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. chronic*.hw.
2. ((chronic* or persistent or long* term or ongoing or degenerative) adj3 (disease* or disab* or ill* or condition* or health condition*
or medical condition*)).tw.
3. chronic fatigue syndrome.tw.
4. long term care/
5. long* term care.tw.
6. exp neurodegenerative diseases/
7. (neurodegenerative or Huntington* disease or Parkinson* disease or amyotrophic lateral sclerosis or motor neuron disease).tw.
8. exp multiple sclerosis/
9. multiple sclerosis.tw.
10. exp arthritis/
11. (arthritis or osteoarthritis or rheumati*).tw.
12. exp lung diseases obstructive/
13. (obstructive lung disease* or obstructive pulmonary disease* or asthma or bronchitis).tw.
14. exp emphysema/
15. exp pulmonary emphysema/
16. emphysema.tw.
17. exp diabetes mellitus/
18. (diabetes or diabetic).tw.
19. exp hypertension/
20. (hypertension or high blood pressure).tw.
21. exp cerebrovascular disorders/
22. (cerebrovascular disease* or cerebrovascular disorder* or brain ischaemia or cerebral infarction or carotid artery disease* or stroke).tw.
23. exp dementia/
24. (dementia or alzheimer*).tw.
25. exp epilepsy/
26. epilep*.tw.
27. exp myocardial ischaemia/
28. (myocardial ischaemia or angina pectoris or coronary disease* or coronary artery disease* or myocardial infarction).tw.
29. exp heart failure/
30. (heart failure or heart disease*).tw.
31. renal insufficiency/
32. ((renal or kidney) adj (failure* or insufficienc*)).tw.
33. exp colonic diseases/
34. (colonic disease* or colitis or irritable bowel syndrome).tw.
35. exp obesity/
36. (obesity or obese).tw.
37. exp hiv/






44. (cancer* or oncolog* or neoplasm* or carcinom* or tumo?r* or malignan*).tw.
45. or/1-44
46. teaching materials/
47. computer assisted instruction/
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48. ((teaching or education* or instruction* or information* or counsel* or train* or self care or self management) adj2 (material* or
pack*)).tw.
49. ((written or print* or online or on-line or electronic or computeri#ed or computer-based or web-based or internet-based) adj2
(information or education or material* or pack* or intervention*)).tw.
50. patient held.tw.
51. pamphlets/
52. ((patient? or carer* or caregiver* or care giver* or parent? or self care or self management or self-education*) adj5 (guide* or manual?
or booklet? or brochure? or checklist* or folder* or care plan* or management plan* or clinical information)).tw.
53. ((self care or self management or self-education*) and (print* or written or mail* or web* or internet or online or on line or
electronic* or email* e-mail* or electronic mail)).tw.
54. patient education as topic/
55. patient education.tw.




60. (e-mail* or email* or web* or internet or online or on line or electronic* or print* or written or guide* or manual? or booklet? or
brochure? or checklist* or folder* or care plan* or management plan*).tw.
61. or/58-60
62. 57 and 61
63. or/46-53
64. 62 or 63
65. 45 and 64
66. randomized controlled trial.pt.
67. controlled clinical trial.pt.
68. randomized.ab.
69. placebo.ab.




74. exp animals/ not humans.sh.
75. 73 not 74
76. 65 and 75
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